Table 3.

Summary of efficacy.

	Median TIP (95% CI)	6-month tumor PFS# (95% CI)	12-month tumor PFS# (95% CI)	Median OS (95% CI)	6-month survival (95% CI)	12-month survival (95% CI)
Ablation (n = 12)	7.4 months (2.8 months- undefined)	58.3% (27.0–80.1%)	31.3% (8.5–57.8%)	10.1 months (4.6–15.7 months)	75.0% (40.8–91.2%)	46.9% (17.6–71.8%)
TACE (n = 11)	7.4 months (2.2–19.4 months)	63.6% (29.7–84.5%)	29.1% (5.4–59.3%)	13.6 months (7.5 months- undefined)	90.9% (50.8–98.7%)	80.8% (42.4–94.9%)
Total population, excluding N = 5 on phase I (n = 23)	7.4 months 4.6–19.4 months)	60.9% (38.3–77.4%)	30.9% (12.8–51.1%)	12.8 months (7.8–15.7 months)	82.6% (60.9–93.1%)	62.3% (38.1–79.3%)
Total population (n = 28)	7.4 months (4.7–19.4 months)	57.1% (37.1–72.9%)	33.1% (16.2–51.2%)	12.3 months (9.3–15.4 months)	85.7% (66.3–94.4%)	50.8% (29.1–68.9%)

CI, confidence interval; OS, overall survival.

^#Tumor progression-free survival (PFS) refers to probabilities associated with time to tumor progression (TTP).